Exelixis' TKI falls short in colorectal cancer subgroup as FDA reviews approval in all-comers on June 23, 2026 atezolizumab Colorectal Carcinoma Exelixis mCRC Metastasis from malignant neoplasm of colon and/or rectum Overall Survival Phase 3 regorafenib STELLAR-303 Stivarga Subgroup A Nepoviruses TKI zanzalintinib +
Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025 on October 20, 2025 adjuvant treatment atezolizumab ctDNA-guided therapy Disease-Free Survival ESMO IMvigor011 Malignant neoplasm of urinary bladder muscle-invasive bladder cancer Overall Survival Tecentriq +
Exelixis' Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study on June 24, 2025 atezolizumab checkpoint inhibitor Clinical Trials Colorectal Carcinoma Exelixis Overall Survival STELLAR-303 Stivarga zanzalintinib +
Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025 on May 23, 2025 ASCO atezolizumab IMforte trial Jazz lurbinectedin Malignant neoplasm of lung Overall Survival Progression-Free Survival Small cell carcinoma of lung Tecentriq Zepzelca +